We are live on ! Find out more
OPK icon

Opko Health

1.61 USD
-0.08
4.73%
At close Updated Nov 19, 4:00 PM EST
Pre-market
After hours
1.60
-0.01
0.62%
1 day
-4.73%
5 days
-3.59%
1 month
0%
3 months
10.27%
6 months
40%
Year to date
26.77%
1 year
22.9%
5 years
-62.99%
10 years
-84.58%
 

About: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

Employees: 2,275

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 29.4%
Neutral 58.8%
Negative 11.8%
Neutral
Zacks Investment Research
1 day ago
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health's Global Products growth, partnered therapies and advancing pipeline support its outlook, but clinical risks and market headwinds pose challenges.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
Neutral
MarketBeat
15 days ago
What OPKO Health (OPK) Said on Its Q3 Earnings Call
OPKO Health NASDAQ: OPK reported 16% growth in third-quarter revenue from continuing operations and outlined plans to focus on drug development and pharmaceutical products following its proposed sale of BioReference assets to Labcorp.
What OPKO Health (OPK) Said on Its Q3 Earnings Call
Neutral
Seeking Alpha
15 days ago
OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript
Negative
Zacks Investment Research
15 days ago
OPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.03 per share a year ago.
OPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
15 days ago
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026. Third Quarter 2026 and Recent Business Highlights OPKO enters into agreement with Labcorp for the sale of substantially all remaining BioReference diagnostic operations.
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
Neutral
GlobeNewsWire
22 days ago
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 on Wednesday, November 4, 2026. OPKO's senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
Neutral
GlobeNewsWire
24 days ago
OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational, long acting human growth hormone receptor antagonist being developed for the treatment of acromegaly.
OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
Positive
Zacks Investment Research
1 month ago
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
Positive
Benzinga
1 month ago
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
Labcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire select assets of BioReference Health from OPKO Health Inc. (NASDAQ:OPK) in a deal worth up to $872 million.
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
Positive
Benzinga
1 month ago
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on Thursday.
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday
Price charts implemented using Lightweight Charts™